Abstract PO4-04-01: Antitumor activity and safety of sacibertinib (Hemay022) in combination with endocrine therapy in patients with ER and HER2 both positive metastatic breast cancer: A phase Ib study
Authors: Hui-Ping Li, Qingyuan Zhang, Ruyan Zhang, Yaxin Liu, Xianjun Hu
Published: 2024-05-02
DOI:
10.1158/1538-7445.sabcs23-po4-04-01
Source:
Full article
Abstract
Abstract